M. Franco G. Salvoza

Array ( [id] => 13077097 [patent_doc_number] => 10058603 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-08-28 [patent_title] => Vaccine [patent_app_type] => utility [patent_app_number] => 14/774729 [patent_app_country] => US [patent_app_date] => 2014-03-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 28 [patent_figures_cnt] => 32 [patent_no_of_words] => 21133 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 45 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14774729 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10669657 [patent_doc_number] => 20160015802 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-01-21 [patent_title] => 'COMPOSITIONS AND METHODS TO TREAT AIDS' [patent_app_type] => utility [patent_app_number] => 14/776682 [patent_app_country] => US [patent_app_date] => 2014-03-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 15961 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14776682 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10635664 [patent_doc_number] => 09353158 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-05-31 [patent_title] => 'Hepatitis B virus vaccines' [patent_app_type] => utility [patent_app_number] => 14/207135 [patent_app_country] => US [patent_app_date] => 2014-03-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 52 [patent_figures_cnt] => 42 [patent_no_of_words] => 14805 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 41 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14207135 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9568683 [patent_doc_number] => 20140186396 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-07-03 [patent_title] => 'METHODS FOR STABILIZING INFLUENZA ANTIGEN ENVELOPED VIRUS-BASED VIRUS-LIKE PARTICLE SOLUTIONS' [patent_app_type] => utility [patent_app_number] => 14/199887 [patent_app_country] => US [patent_app_date] => 2014-03-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 24410 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14199887 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10367365 [patent_doc_number] => 20150252370 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-09-10 [patent_title] => 'USE OF ATX INHIBITORS FOR TREATMENT OR PREVENTION OF INFLUENZA VIRUS A INFECTIONS' [patent_app_type] => utility [patent_app_number] => 14/196365 [patent_app_country] => US [patent_app_date] => 2014-03-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 9559 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14196365 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12143766 [patent_doc_number] => 09878002 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-01-30 [patent_title] => 'Compositions and methods involving endogenous retrovirus proteins' [patent_app_type] => utility [patent_app_number] => 14/762856 [patent_app_country] => US [patent_app_date] => 2014-01-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 20 [patent_no_of_words] => 12516 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 51 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14762856 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9477143 [patent_doc_number] => 20140134606 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-05-15 [patent_title] => 'EXOSOME-MEDIATED DIAGNOSIS OF HEPATITIS VIRUS INFECTIONS AND DISEASES' [patent_app_type] => utility [patent_app_number] => 14/159612 [patent_app_country] => US [patent_app_date] => 2014-01-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 15442 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14159612 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10553934 [patent_doc_number] => 09278128 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-03-08 [patent_title] => 'Vaccines and immunotherapeutics comprising IL-15 receptor alpha and/or nucleic acid molecules encoding the same, and methods for using the same' [patent_app_type] => utility [patent_app_number] => 14/148359 [patent_app_country] => US [patent_app_date] => 2014-01-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 25 [patent_no_of_words] => 17335 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 10 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14148359 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12306525 [patent_doc_number] => 09938541 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-04-10 [patent_title] => AAV variant [patent_app_type] => utility [patent_app_number] => 14/649603 [patent_app_country] => US [patent_app_date] => 2013-12-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 8424 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 61 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14649603 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11922706 [patent_doc_number] => 09790276 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-10-17 [patent_title] => 'Glycan-modified anti-CD4 antibodies for HIV prevention and therapy' [patent_app_type] => utility [patent_app_number] => 14/132667 [patent_app_country] => US [patent_app_date] => 2013-12-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 14 [patent_no_of_words] => 13920 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 70 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14132667 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11922706 [patent_doc_number] => 09790276 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-10-17 [patent_title] => 'Glycan-modified anti-CD4 antibodies for HIV prevention and therapy' [patent_app_type] => utility [patent_app_number] => 14/132667 [patent_app_country] => US [patent_app_date] => 2013-12-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 14 [patent_no_of_words] => 13920 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 70 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14132667 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10421192 [patent_doc_number] => 20150306204 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-10-29 [patent_title] => 'VACCINE COMPOSITION FOR USE IN IMMUNO-COMPROMISED POPULATIONS' [patent_app_type] => utility [patent_app_number] => 14/650807 [patent_app_country] => US [patent_app_date] => 2013-12-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 18149 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14650807 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10421193 [patent_doc_number] => 20150306205 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-10-29 [patent_title] => 'VACCINE COMPOSITION FOR NAIVE SUBJECTS' [patent_app_type] => utility [patent_app_number] => 14/650809 [patent_app_country] => US [patent_app_date] => 2013-12-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 16441 [patent_no_of_claims] => 35 [patent_no_of_ind_claims] => 33 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14650809 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9408086 [patent_doc_number] => 20140099338 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-04-10 [patent_title] => 'YEAST EXPRESSED CLASSICAL SWINE FEVER VIRUS GLYCOPROTEIN E2 AND USE THEREOF' [patent_app_type] => utility [patent_app_number] => 14/106761 [patent_app_country] => US [patent_app_date] => 2013-12-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 2673 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14106761 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9537190 [patent_doc_number] => 20140161837 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-06-12 [patent_title] => 'VACCINE ADJUVANT, VACCINE COMPOSITION AND METHOD FOR PREPARING A VACCINE ADJUVANT' [patent_app_type] => utility [patent_app_number] => 14/101044 [patent_app_country] => US [patent_app_date] => 2013-12-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 20 [patent_no_of_words] => 7385 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14101044 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9517793 [patent_doc_number] => 20140154285 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-06-05 [patent_title] => 'FUSION PROTEINS FOR USE AS IMMUNOGENIC ENHANCERS FOR INDUCING ANTIGEN-SPECIFIC T CELL RESPONSES' [patent_app_type] => utility [patent_app_number] => 14/095760 [patent_app_country] => US [patent_app_date] => 2013-12-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 8744 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14095760 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13051925 [patent_doc_number] => 10047347 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-08-14 [patent_title] => Oncolytic adenoviruses with increased proportion of the 156R splicing isoform of the E1B protein [patent_app_type] => utility [patent_app_number] => 14/648661 [patent_app_country] => US [patent_app_date] => 2013-11-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 16 [patent_no_of_words] => 15194 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 99 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14648661 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13182555 [patent_doc_number] => 10106781 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-10-23 [patent_title] => Recombinant adenoviruses and use thereof [patent_app_type] => utility [patent_app_number] => 14/443299 [patent_app_country] => US [patent_app_date] => 2013-11-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 29 [patent_figures_cnt] => 29 [patent_no_of_words] => 17587 [patent_no_of_claims] => 44 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 73 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14443299 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11388745 [patent_doc_number] => 09549976 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2017-01-24 [patent_title] => 'Affinity selection of Nipah and Hendra virus-related vaccine candidates from a complex random peptide library displayed on bacteriophage virus-like particles' [patent_app_type] => utility [patent_app_number] => 14/081629 [patent_app_country] => US [patent_app_date] => 2013-11-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 8857 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 237 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14081629 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10643623 [patent_doc_number] => 09360485 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-06-07 [patent_title] => 'Eukaryotic expression system and use thereof' [patent_app_type] => utility [patent_app_number] => 14/070850 [patent_app_country] => US [patent_app_date] => 2013-11-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 17 [patent_no_of_words] => 6115 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 101 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14070850 [rel_patent_id] =>[rel_patent_doc_number] =>)